Akers Biosciences starts asthma assay trials
This article was originally published in Clinica
Executive Summary
Akers Biosciences has begun clinical trials of its rapid point-of-care test for asthma in around 200 patients. The disposable Breath Asthma Check assay measures the acidity of exhaled breath condensate; this indicates airway acidity, which is associated with airway inflammation. The test could provide an inexpensive, rapid screening aid in the diagnosis of early-stage asthma, and may also be used as a compliance tool for physicians to ensure successful drug therapy regimens. Thorofare, New Jersey-based Akers will use the trial results to submit regulatory approval applications for the test in the US and EU. This is scheduled for the third quarter of 2011.
You may also be interested in...
ITF Has A Fight On Its Hands In Duchenne
The group’s new muscular dystrophy pill seems unlikely to cut into Sarepta’s sales.
AbbVie Needs To Freshen Up
With half of its 2023 sales coming from aging blockbusters like Humira and Botox, AbbVie needs new blood.
AstraZeneca Pays $2bn To Keep Up With The Joneses
Bristol Myers Squibb and Lilly have recently done billion-dollar radiopharmaceuticals deals, and now the UK group wants a piece of the market. But can it make its Fusion fusion work?